ArsenalBio
PrivateLast Round
Series C
Sep 4, 2024
Total Funding Raised
$630M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
ArsenalBio is a biotechnology company that discovers and develops programmable autologous T cell therapies for the treatment of solid tumors.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ArsenalBio Comparables
Compare ArsenalBio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Outpace Bio | 84% | |
| OverT Bio | 78% | |
| Dispatch Biotherapeutics | 77% |
For institutional investors. Book with your work email.
ArsenalBio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Sep 4, 2024 | ||||
| Series B | Sep 6, 2022 | ||||
| Series A | Oct 17, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
ArsenalBio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SoftBank Investment Advisers | Series C, Series B |
| Westlake Village BioPartners | Series C, Series B, Series A |
| HV Fund | Series C, Series B |
| Waycross Ventures | Series B |
| Parker Institute for Cancer Immunotherapy | Series B, Series A, Series C |
| Sixth Street Partners | Series B |
| Osage University Partners | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 25, 2025
Company is testing CAR T-cell therapies in human trials.
- Jan 13, 2025
CEO to present at the J.P. Morgan Healthcare Conference on Jan 13, 2025.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- decreases_headcount_bySep 2, 2026
Arsenal Biosciences, Inc. decreased headcount by 99 on Aug 31st '26.
For institutional investors. Book with your work email.
ArsenalBio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about ArsenalBio's valuation, stock price, and market status.
Is ArsenalBio a public or private company?
ArsenalBio is a private company.
What is the current stock price of ArsenalBio?
ArsenalBio is a private company, so its shares have no public market price. Caplight tracks ArsenalBio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is ArsenalBio worth (valuation)?
Valuation information for ArsenalBio is not publicly available.
Can I buy ArsenalBio stock?
ArsenalBio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was ArsenalBio's last funding round?
ArsenalBio's most recent funding round was Series C on September 4, 2024.
Who are the main investors in ArsenalBio?
Key investors in ArsenalBio include SoftBank Investment Advisers, Westlake Village BioPartners, SoftBank Group, ARCH Venture Partners, Luma Group.
Will ArsenalBio IPO soon?
No public IPO plans have been announced for ArsenalBio.
How can I track ArsenalBio secondary market activity?
Caplight tracks bids, offers, and trades in ArsenalBio's shares on secondary markets.